Drugs / HRS-7249
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06541457 | Aug 2024 → Jul 2025 | hyperlipidemia | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07308392 | Feb 2026 → Jun 2027 expected | metabolic disease | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07100418 | Aug 2025 → Sep 2026 overdue | hyperlipidemia | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7249 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07308392 ↗ |
| Route | Subcutaneous | “Single Subcutaneous Injection of HRS-7249” NCT06541457 ↗ |